O-304

weak data

Also seen as: ATX-304

The Dose Guy’s verdict

Sep 1, 2026
2 sources

O-304 is the most interesting AMPK activator on the shelf because it has early human signals where the rest of this class has none. But “early” means early. The published literature is mice and cells only, the human work is conference-stage, and nobody has measured what it does to body composition in a person. Worth watching, genuinely, but not worth running today. If you want an AMPK-mediated metabolic floor right now, metformin has sixty years of human data behind it.

Would I take it?Caution, worth watching, not worth running.

What it is

A pan-AMPK activator, meaning it turns on all forms of the enzyme your cells use to sense low energy and switch on fat burning, glucose uptake, and mitochondrial work. AMPK is the same switch exercise flips, and the same one metformin nudges at a gentler, clinical dose. The trouble with dedicated AMPK activators is that they tend to only work in rodents or require doses no human could practically run. O-304 is the exception that has at least reached humans, with early clinical work in type 2 diabetics showing improved insulin sensitivity and blood flow, though that data sits at the conference-presentation stage and has not made it to a published paper.

On the weight-loss shelf it sits near the other exercise-mimetic hopefuls, SLU-PP-332 and AICAR, but O-304 is ahead of both in the one way that matters: someone has given it to a person.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published evidence is preclinical only. The human work exists but has not reached a journal:

In a mouse model of progressive fatty liver disease, O-304 reduced body fat, lowered cholesterol, and mitigated liver steatosis and slowed the development of liver fibrosis.JCI Insight 2025 · mouse MASLD model

In cisplatin-induced kidney injury, O-304 cut serum creatinine from 0.05 to 0.02 mM versus controls, with p=0.03, confirming on-target AMPK activity in vivo.Biomed Pharmacother 2024 · mouse kidney injury

No published human clinical study of O-304 appears in the PubMed corpus.as of Aug 2026

Realistic protocols

No published human dosing data exists for O-304 as a metabolic agent. The early clinical work used oral dosing in type 2 diabetics, but the specifics live in conference abstracts, not a published protocol I can stand behind. If the full trial data publishes, this section gets rewritten. Until then, there is nothing here to build on.